Mast cells are bone marrow-derived effector cells that can initiate inflammatory responses to infectious organisms or allergens by releasing a multitude of pro-inflammatory factors including prostaglandin (PG) D 2 . We demonstrate that primary murine bone marrow-derived mast cells (BMMCs) express the PGD 2 receptor; chemoattractant receptor-homologous molecule expressed on T h class 2 cells (CRT h 2). Activation of CRT h 2 on BMMC by PGD 2 or the CRT h 2-specific agonist, 13,14-dihydro-15-keto-prostaglandin D 2 (DK-PGD 2 ), resulted in signaling response including Ca 21 mobilization and phosphorylation of the p42/p44 extracellular signal-regulated kinases (ERKs) kinases. Phosphorylation of the ERKs could be blocked by pertussis toxin, as well as a small molecule antagonist of CRT h 2, Compound A. Activation of CRT h 2 on BMMC also resulted in the upregulation of CD23 and CD30 on the cell surface, as well as CD62L shedding. Finally, PGD 2 and DK-PGD 2 induced the migration of BMMC in vitro and in vivo in response to an intra-dermal DK-PGD 2 injection. Both these processes were inhibited by the CRT h 2 antagonist. These results raise the possibility that the functional consequences of the PGD 2 -CRT h 2 interaction on mast cells may be relevant in allergic inflammation.
Introduction
Mast cells are resident cells present in all organs of the body and are known to increase in number at sites of inflammation (1, 2) . They play a role in host defense to helminthic parasites and certain bacteria and are major effectors for the induction of inflammation and allergic reactions (3) . Mast cells arise from CD34 + /CD117 + pluripotent hematopoietic stem cells in the bone marrow and mature to committed progenitors upon growth factor stimulation (4) . These progenitors are released into the circulation from the bone marrow and subsequently migrate to various tissues of the body where local tissue-specific factors and cell surface interactions determine the mature phenotype of the mast cell appropriate for the microenvironment (5, 6) . Two major subtypes of mast cells have been identified, connective tissue mast cells that are found in the skin, around blood vessels and the peritoneal cavity. Mucosal mast cells are found in the gut and the upper airways (7, 8) .
Mast cells bind IgE via expression of the high affinity IgE receptor FceRI, and it is via FceRI that mast cells are most commonly activated in allergic diseases. Aggregation of receptor-bound IgE molecules by polyvalent antigen triggers a signaling cascade resulting in mast cell activation and rapid degranulation of preformed pro-inflammatory mediators, which include histamine, proteases and proteoglycans. Protein mediators such as cytokines and chemokines are also synthesized and released, as are de novo synthesized lipids such as leukotriene (LT) C 4 and LTB 4 and prostaglandin (PG) D 2 . The generation and release of these factors by mast cells induces a strong inflammatory response and contributes to the pathogenesis of various allergic diseases, such as asthma, allergic rhinitis and atopic dermatitis (9, 10) . PGD 2 is an arachidonic acid metabolite that has been implicated in the development and progression of various allergic diseases. Following the conversion of arachidonic acid to PGH 2 by cyclooxygenase, hematopoietic PGD 2 synthase converts PGH 2 into PGD 2 (11) . PGD 2 is then exported from the cytosol to the extracellular space by a PG transporter protein (12) . Two receptors so for have been identified for PGD 2 , prostanoid D1 (DP1) receptor and chemoattractant receptor-homologous molecule expressed on T h class 2 cells (CRT h 2). Both these G protein-coupled receptors bind PGD 2 with nanomolar affinity; however, they share little amino acid homology and have different tissue expression patterns and signaling pathways, suggesting distinct roles in allergic and immune responses (13) . The amino acid sequence of DP1 shows homology to other prostanoid receptors, whereas CRT h 2 shows high identity to chemoattractant G-protein-coupled receptors (GPCRs). DP1 is associated with pertussis toxin (Ptx)-resistant G as , whereas CRT h 2 signals with Ptx-sensitive G ai proteins (14) , similar to chemokine receptors (9) . CRT h 2 is expressed by both T h 2 and a subset of T h 1 T h cells in the mouse, as well as eosinophils and basophils (15, 16) . Human basophils express both DP1 and CRT h 2, and treatment (Tx) with a DP1-selective agonist, BW245C, inhibited FceRI-dependent exocytosis. In contrast, the selective CRT h 2 agonist, 13,14-dihydro-15-keto-prostaglandin D 2 (DK-PGD 2 ), potentiated FceRI-dependent exocytosis (16) . Similarly, DK-PGD 2 , but not BW245C, induced human eosinophil degranulation (17) . Thus, expression of these two receptors on the same cell appears to be playing different and often opposing roles in regulating responsiveness toward PGD 2 .
As mast cells are the largest source of PGD 2 in the body, we investigated whether they express the CRT h 2 receptor. We hypothesized that expression of CRT h 2 by mast cells may result in a positive feedback circuit where mast cell release of PGD 2 could recruit more mast cells to the sites of PGD 2 -mediated inflammation. Moreover, CRT h 2 expression may influence the activation state of mast cells upon PGD 2 stimulation. We show here the evidence that bone marrowderived mast cells (BMMCs) express the CRT h 2 receptor, and using a specific and potent small molecule antagonist demonstrate that signaling through CRT h 2 results in extracellular signal-regulated kinase (ERK) kinase phosphorylation and mast cell chemotaxis both in vitro and in vivo.
Methods

Materials
All reagents were purchased from Sigma (St Louis, MO, USA) unless otherwise stated. The Institutional Animal Care and Use Committee approved all animal experimentation prior to implementation. Compound A is a proprietary, selective and highly potent CRT h 2 small molecular weight antagonist that is developed as part of the Actimis Pharmaceuticals, Inc. portfolio of potent and selective compounds (WO/2004/096777).
Mast cell culture
Mast cells were cultured as described previously (18) . In brief, bone marrow cells were flushed from femurs of the 6-10-week-old C57Bl/6 mice and cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS, 100 lM non-essential amino acids (Mediatech, Herndon, VA, USA), 50 lM 2-ME and 8% conditioned medium of IL-3 gene-transfected cells (BMMC medium). After 4 weeks of culture, >95% of the Trypan blue-excluding viable cells were mast cells. BMMCs used for experimentation were in culture for 4-6 weeks.
Reverse transcription-PCR assay
Messenger RNA from BMMCs was isolated using Oligotex mRNA isolation kit according to the manufacturer's instructions (Qiagen Sciences, Valencia, CA, USA). Reverse transcription (RT)-PCR analysis of CRT h 2 message expression was performed by standard techniques (19) . Briefly, the RT reaction was carried out using isolated RNA, oligo dT 3# primers and reverse transcriptase (Superscript III first strand synthesis system, Invitrogen). PCR was then performed on all the samples using CRT h 2 primers (5# primer, 5# CCTCCCCTTTAGCTCTCTGC 3# and 3# primer, 5# TGA-AGCGTCTAGCGCAGTAA 3#) and actin primers (5# primer, 5# TCACCGAGGCCCCCTGAAC 3# and 3# primer, 5# GCACGCACTGTAATTCCTC 3#). The PCR protocol used to amplify the CRT h 2 and b-actin cDNA was 95°C, 30 s; 55°C, 60 s and 68°C, 2 min for 35 cycles, followed by 72°C for 5 min. The PCR products were visualized on a 1.5% agarose gel stained with ethidium bromide.
Saturation analysis and competitive binding assay
Radioligand-binding analyses were performed according to the methods of Sugimoto et al. (20) . For the competitive binding assay, BMMCs were re-suspended in binding buffer (50 mM Tris-HCl, pH 7.4, 40 mM MgCl 2 , 0.1% BSA) at a concentration of 4 3 10 6 ml À1 at room temperature. Fifty microliters of cell suspension was incubated for 1 h at room temperature with gentle shaking in the presence of 10 ll of [ 3 H]-PGD 2 (3 nM final), 10 ll of competitor (10 À12 -10 À6 dose range) or buffer alone and the final volume adjusted to 100 ll with buffer. Incubations were performed in U-bottom polypropylene 96-well plates (Fisher Scientific, Pittsburgh, PA, USA) for 60 min at room temperature, and the cell suspension was transferred to filtration plates (MAFB, Millipore, Bedford, MA, USA), pre-wet with PEI (0.5%) buffer (Acros Organics, Morris Plains, NJ, USA). The cell pellets were washed three times with buffer and the radioactivity was counted on a TopCount (Packard Bioscience, Meriden, CT, USA). Saturation analysis was done using 10 lM DK-PGD 2 for each experimental condition, and a range of [ 3 H]-PGD 2 (from 0.3 to 10 nM). Data analyses were performed using the Prizm TM graphics program using a one-site competition model (GraphPad Software Inc., San Diego, CA, USA). PGD 2 and DK-PGD 2 were purchased from Cayman Chemical. Radiolabeled PGD 2 {PGD 2 [5, 6, 9, 8, 12, 14, H(N)]; specific activity 160 Ci mmol À1 } was purchased from Perkin Elmer (Waltham, MA, USA).
Flow cytometric analysis
BMMCs were prepared and stained for flow cytometry as previously described (21) . Briefly, the cells were incubated for 10 min with Fc block (Becton Dickinson-Pharmingen) to inhibit non-specific binding. The cells were subsequently incubated on ice and stained with FITC-conjugated anti-CD62L (clone Dreg 56) mAb, PE-conjugated anti-CD30 mAb (clone mCD30.1) or FITC-conjugated anti-CD23 mAb (clone B3B4; all antibodies obtained from BD Pharmingen).
The cells were washed in cold FACS buffer (PBS containing 1% BSA and 0.1% sodium azide) and analyzed using a FACScan II analyzer (Becton Dickinson, Mountain View, CA, USA) and CellQuest software (Becton Dickinson).
Calcium mobilization assay
Murine BMMCs were labeled with 3 lM of indo-1AM dye (Invitrogen) for 60 min at 37°C. The cells were subsequently washed and re-suspended in 1 ml of HBSS containing 1% BSA (fraction V, Sigma). Calcium mobilization was measured using a PTI fluorimeter (South Brunswick, NJ, USA) as previously described (22) . Murine RANTES and eotaxin were obtained from R&D Systems (Minneapolis, MN, USA). A relatively high dose (10 lM) of PGD 2 and PGE 2 was used to stimulate the BMMC in the Ca ++ mobilization experiments shown in Figs 4 and 5(D-G) in order to see a robust response under the experimental conditions used. Lower doses (1 lM) showed only a weak response and, in contrast to the other assays, no response was detected at concentrations <100 nM.
Histamine release assay
BMMCs were cultured overnight in full medium ( . One hundred microliter aliquots were incubated at 37°C for 30 min, and the BMMCs were then treated with either antigen (DNP-BSA, 100 ng ml À1 ) in the presence or absence of PGD 2 , DK-PGD 2 or PGE 2 or the PGs alone. The stimulated cells were incubated for an additional 45 min. At this point, the supernatant was isolated by pelleting the cells by centrifugation, and the histamine levels were determined by ELISA according to the manufacturer's protocol (IBL, Hamburg, Germany).
Measurement of IL-6 production
Mast cells were loaded with antigen-specific IgE as described above in the histamine release assay section. Following two washes, the cells were re-suspended at a concentration of 1 3 10 6 cells ml À1 in full medium. The mast cells were then stimulated with antigen (DNP-BSA, 10 ng ml À1 ) in the presence or absence of PGD 2 , DK-PGD 2 or PGE 2 for 20 h at 37°C. The supernatant was collected and assayed by ELISA for IL-6 according to the manufacturer's directions (R&D Systems).
Western blot analysis
BMMCs were re-suspended in Tyrode's buffer. Stimulation with PGD 2 or DK-PGD 2 was conducted at 37°C and was halted by the addition of cold PBS. The cells were then centrifuged at 4°C and immediately re-suspended in 13 RIPA buffer (Pierce, Rockford, IL, USA) containing freshly added protease and phosphatase inhibitors. The cells were vortex mixed briefly, incubated on ice for 15 min and subsequently centrifuged to pellet-insoluble material. The supernatants were isolated, boiled for 5 min in 23 Laemmli sample buffer and loaded onto 10% Tris-glycine polyacrylamide gels (Invitrogen). Protein was transferred onto a nitrocellulose membrane using the iBlot dry blotting system (Invitrogen). Following transfer, the immunoblots were handled essentially as described previously (21) . Briefly, the nitrocellulose membrane was incubated in 13 Tris-buffered saline [20 mM Tris-HCl (pH 7.6) and 137.5 mM NaCl], 0.1% Tween 20 with 5% w/v non-fat dry milk (Cell Signaling Technologies, Boston, MA, USA) for 1 h at 25°C to block non-specific proteinbinding sites. The membrane was then incubated at 4°C overnight with p42/p44 anti-phospho-ERK antibody (Cell Signaling Technologies) diluted 1/1000. The immunoblots were subsequently washed in TTBS [20 mM Tris-HCl (pH 7.6), 137.5 mM NaCl and 0.1% Tween 20] and incubated with peroxidase-conjugated goat anti-rabbit IgG (Pierce) diluted 1/5000 for 1 h at 25°C. Phospho-MAPK was visualized using the chemiluminescent peroxidase substrate Super Signal West Femto Maximum Sensitivity Substrate (Pierce). For subsequent blotting, the membrane was stripped using Restore Western Blot Stripping Buffer (Pierce) for 30 min at 25°C. The anti-MAPK blot was conducted in the same manner, except the primary antibody was a rabbit anti-ERK polyclonal antibody at 1/1000 (Cell Signaling Technologies). The anti-CRT h 2 blot was hybridized with an anti-CRT h 2 polyclonal antibody from Cayman Chemical. The western blot results were visualized using a Kodak Gel Logic 440 Imaging System (Eastman Kodak, New Haven, CT, USA).
Chemotaxis assay
All chemotaxis assays were performed in a 48-well modified Boyden chamber (Neuroprobe, Cabin John, MD, USA) as described (21) . BMMCs were re-suspended in RPMI 1640 (Invitrogen) with 10% FBS (Lonza Biowhittaker, Portsmouth, NH, USA) at 2 3 10 6 cells ml
À1
. Twenty-five microliters of medium or medium containing PGD 2 or DK-PGD 2 (Cayman Chemical) at varying concentrations were added to the bottom of the chamber. A 5-lm pore size polyvinyl-pyrrolidone free polycarbonate filter (Osmotics, Livermore, CA, USA) was overlayed, and 1 3 10 5 BMMCs were added to the upper chamber. Where indicated, mast cells were pre-incubated with either PD98059 (Calbiochem, San Diego, CA, USA) at 10 lM or Compound A at indicated concentrations for 15 min at 37°C. Cells were allowed to migrate for 1 h at 37°C, after which time the filter was stained in Diff-Quik (Baxter, Deerfield, IL, USA). Migrating cells were quantified by microscopy, manually counting four fields per well under high power (3400). The assays were performed in duplicate, and the results are shown as the average number of cells enumerated per condition 6SEM.
In vivo chemotaxis assay
In vivo migration was carried out similar to that described previously (23) . C57Bl/6 mice (4-to 6-week-old female) (Jackson Laboratories, Bar Harbor, ME, USA) were orally dosed with either Compound A (10, 1 and 0.1 mg kg À1 ) or delivery vehicle prior to having their dorsal skin shaved and receiving an intra-dermal (i.d.) injection of DK-PGD 2 (3 lg DK-PGD 2 dissolved in a 50 ll volume of PBS and controls received PBS only). A total of 2.5 3 10 6 BMMCs suspended in 100 ll of Tyrode's buffer were then intravenously (i.v.) injected into the recipient animals. One hour after the i.v. transfer of BMMC, the dorsal skin surrounding the i.d. injection was isolated and snap frozen in OCT medium (Tissue Tech, Torrance, CA, USA). The skin samples were then sectioned and stained with Toluidine blue to allow visualization of mast cells. The number of mast cells was determined by counting the number of Toluidine blue staining cells per high-power field (hpf) (3400). A minimum of 9 hpf was counted for each skin section by a blinded reviewer. There were four mice in each Tx group. The results display the mean number of mast cells per hpf 6 SEM, and statistical significance was determined by the one-way analysis of variance test.
Results
CRT h 2 mRNA and protein are expressed by BMMCs
To investigate whether primary BMMC express the CRT h 2 receptor, RNA isolated from these cells were subjected to RT-PCR analysis. As shown in Fig. 1(A) , BMMC RNA shows a PCR product of the expected size (694 bp). Protein lysates made from BMMC were analyzed by western analysis. A specific 62 kDa band was observed at the expected molecular weight of the glycosylated form of the receptor (Fig. 1B) . Collectively, these results demonstrated that CRT h 2 is transcribed and translated by primary BMMCs.
Pharmacological characterization of CRT h 2 on BMMC
Saturation analysis and competitive binding assays were performed with BMMC using [ 3 H]-labeled PGD 2 and non-labeled DK-PGD 2 , which is a CRT h 2-specific ligand. These experiments showed an expected K d of 2.9 6 1.1 nM, and the B max was 300.5 6 50.1 pM ( Fig. 2A and B) . The receptor number per cell was calculated to be 1065 6 167 receptor sites per cell. This data confirm functional cell surface expression of CRT h 2 on BMMC.
CRT h 2 activation modulates expression of cell surface molecules
Murine primary BMMCs were cultured in the presence of 50 nM DK-PGD 2 for 15 min, and levels of CD62L (L-selectin) was assessed by flow cytometry. As shown in Fig. 3(A) , there was a reduced amount of cell surface CD62L following DK-PGD 2 Tx, indicating the BMMC shed L-selectin. Incubating the cells with DK-PGD 2 for longer time periods (30 and 45 min) did not appreciably increase the amount of L-selectin shedding. When BMMCs were cultured with 50 nM DK-PGD 2 for 12 h, there was a large increase in CD23, the low affinity IgE receptor (FceRII) cell surface expression (Fig. 3B) , and a modest increase in the tumor necrosis factor (TNF) receptor superfamily member CD30 expression (Fig. 3C) . DK-PGD 2 -mediated activation of CRT h 2 did not modulate the cell surface expression of FceRI, CD40 ligand, OX-40 ligand, 4-1BB, CD28, CD11b, CD18 or CD117 (data not shown).
Activation of BMMC with PGD 2 results in the mobilization of intracellular calcium
As CRT h 2 has been shown to be G ai -linked GPCR, we examined BMMC for the ability to mobilize intracellular calcium stores as an early response in the signaling cascade upon PGD 2 stimulation. As shown in Fig. 4 , PGD 2 stimulation resulted in a transient Ca 2+ mobilization, and this response was blocked by Ptx pre-Tx (data not shown). No crossdesensitization was observed when BMMCs were first treated with PGD 2 followed by the CCR3 agonist chemokine CCL5 (RANTES), or inversely, treated with RANTES prior to the addition of PGD 2 . In contrast to FceRI-induced Ca ++ mobilization, the flux detected with either PGD 2 or the chemokines RANTES and eotaxin are both transient and of relatively low magnitude. Additionally, the magnitude of the PGD 2 -induced Ca ++ flux can be explained by the relatively low CRT h 2 expression on the cell surface, as determined by saturation analysis (Fig. 2) .
PGD 2 does not augment antigen-mediated degranulation or cytokine production
Activation of mast cells via polyvalent antigen cross-linking of IgE bound to FceRI receptors results in degranulation and cytokine production and the prostanoid PGE 2 has previously been shown to enhance both responses (25) (26) (27) . The PGE 2 receptor, EP3, and CRT h 2 are both G ai -linked G protein-coupled receptors and we investigated whether PGD 2 could modify these responses also. As shown in Fig. 5(A) , neither PGD 2 nor PGE 2 caused histamine release by mast cells when added in the absence of antigen. However, when given together with antigen to BMMC loaded with IgE, the co-administration of PGE 2 caused an increased release of histamine compared with antigen alone. On the other hand, Fig. 1 . BMMCs express CRT h 2 mRNA and protein. (A) Total RNA was isolated from BMMC, reverse transcribed and amplified by PCR using CRT h 2 or actin specific primers. A control PCR containing RNA that did not undergo a reverse transcriptase reaction was negative. Importantly, this demonstrates that the product amplified is not from contaminating DNA, which is a possibility since the coding region of CRT h 2 is contained on one exon (24) . (B) Western analysis of protein lysates were made from either BMMC or HELA cells and hybridized with an anti-CRT h 2 polyclonal antibody, revealing a 62 kDa band corresponding to the glycosylated form of the receptor.
neither PGD 2 nor DK-PGD 2 had any significant effect on antigen-mediated histamine release. We investigated this further by next examining IL-6 production. IL-6 has been reported to be released by mast cells upon PGE 2 stimulation alone, as well as after FceRI-mediated activation (26) . We observed that PGE 2 stimulation of BMMC resulted in IL-6 production, whereas PGD 2 or DK-PGD 2 did not (Fig. 5B) . In contrast to PGE 2 , the addition of PGD 2 together with antigen did not increase IL-6 production in IgE-loaded BMMCs when compared with antigen Tx alone (Fig. 5C ). We also observed a similar lack of a PGD 2 or DK-PGD 2 effect on TNF-a and IL-2 production (data not shown). These results show a clear functional difference between the prostanoids PGD 2 and PGE 2 on IgE-loaded BMMC. To explore this further, we examined the ability of PGD 2 and PGE 2 to induce Ca ++ mobilization in IgE-loaded BMMC and as a side-by-side control, non-IgE-loaded BMMC. As shown in Fig. 4 (Fig. 5E) . We further examined whether the addition of PGD 2 could modulate calcium mobilization induced by FceRI-mediated activation. Figure 5(F) shows an antigen dose titration showing FceRI-induced Ca ++ mobilization results in a robust and more sustained calcium flux than either of the prostanoids or chemokines examined. A possible reason for this difference is that G protein-coupled receptors linked to G ai release only intracellular Ca ++ stores in response to activation. FceRI, on the other hand, also induces a Ca ++ ion influx via SOCC channels, resulting in a much more robust and sustained flux (28, 29) . As the amount of antigen decreased, the magnitude of the calcium flux both decreased and was delayed (Fig. 5F ). We tested whether PGD 2 or PGE 2 could modulate calcium mobilization at the lowest dose of antigen tested. As shown in Fig. 5(G) , the addition of PGE 2 and 0.1 ng ml À1 antigen resulted in a more rapid calcium flux, where PGD 2 had no significant effect. The inability of PGD 2 to effect calcium mobilization by IgE-loaded BMMC is entirely consistent with the absence of a PGD 2 effect on histamine release and IL-6 production. The non-responsiveness of BMMC loaded with IgE overnight may be due to CRT h 2 down-regulation, as human T h 2 T lymphocytes down-modulate CRT h 2 mRNA expression upon TCR ligation (30) . As no anti-mouse CRT h 2 antibody is available for FACS analysis, we examined CRT h 2 mRNA levels in untreated BMMC and BMMC loaded with IgE for 18 h (Fig. 5H) . RT-PCR analysis revealed that CRT h 2 mRNA levels are dramatically decreased upon IgE binding, and this may explain, at least in part, the inability of PGD 2 to modulate FceRI-mediated histamine release and cytokine production.
CRT h 2 activation leads to the phosphorylation of ERK1 and ERK2 in primary BMMC
We next investigated whether CRT h 2 stimulation could result in the phosphorylation of p42/44 ERK kinases. It has previously been shown for chemokine receptor activation and subsequent cellular migration that MEK-mediated ERK phosphorylation is a necessary event for actin rearrangement and chemotaxis (21) . The PGD 2 -CRT h 2 interaction has been demonstrated to induce the chemotaxis of T lymphocytes, eosinophils and basophils. As shown in Fig. 6(A) , the addition of either PGD 2 or DK-PGD 2 induces ERK phosphorylation, whereas pre-Tx of the cells for 15 min with the MEK inhibitor PD98059 greatly reduced the levels of ERK phosphorylation. Kinetic analysis showed that the ERKs are phosphorylated within 1 min after the addition of DK-PGD 2 , reaching a maximum at 15 min (Fig. 6B) . Dose titration analysis demonstrated that a concentration as low as 10 À10 M of DK-PGD 2 is sufficient for BMMC to phosphorylate the p42/44 ERK kinases, and the level of phosphorylation increased through 10 À7 M. These results demonstrate that BMMC phosphorylation of the ERK kinases due to DK-PGD 2 stimulation is both time and dose dependent, and this activation occurs via a MEK-dependent pathway.
We next asked whether Compound A could inhibit CRT h 2 activation-dependent ERK phosphorylation. BMMC were pre-treated with various concentrations of Compound A for 10 min prior to the addition of 10 À7 M DK-PGD 2 . As shown in Fig. 6(C) , Compound A inhibited ERK phosphorylation following an incubation with DK-PGD 2 for 15 min, and the inhibition seen was dose dependent. The level of ERK phosphorylation was reduced to background levels following Tx of BMMC with 10 À8 M of the CRT h 2 antagonist. Similar results were seen when the BMMCs were stimulated with 10 À7 M PGD 2 (Fig. 6D) . As Compound A is specific for CRT h 2, in contrast with PGD 2 which can bind and activate both the CRT h 2 and DP1 receptors, these results demonstrate that BMMC ERK phosphorylation in response to PGD 2 stimulation occurs via CRT h 2-mediated pathway.
CRT h 2 activation induces chemotaxis of bone marrow-derived mast cells
As CRT h 2 activation can induce signaling responses in primary BMMCs that are necessary for chemotaxis in other cell types (21), we examined whether PGD 2 or DK-PGD 2 stimulation can induce a chemotactic response. Chemotaxis assays, using a modified Boyden chamber, demonstrated that both ligands could elicit directed migration of BMMC in a dose-dependent manner (Fig. 7A) . Interestingly, DK-PGD 2 -mediated chemotaxis was maximal at 10 À9 M, whereas maximal PGD 2 -induced migration occurred at 10 À8 M. The decreased efficacy seen with PGD 2 may be due to DP1 receptor expression on BMMC, as activation of DP1 has been shown to inhibit chemotaxis of other cells (31) . In line with this, pre-Tx of BMMC with Ptx prior to CRT h 2 activation by either PGD 2 or DK-PGD 2 blocked all chemotaxis (Fig. 7A) . As the DP1 receptor is linked to G as , and is not Ptx sensitive, this provides further evidence that CRT h 2, which is G ai coupled, is mediating the chemotaxis observed. Inhibition of CRT h 2 by the specific antagonist, Compound A, was able to block both PGD 2 -and DK-PGD 2 -induced chemotaxis (Fig. 7B) . Compound A was effective at concentrations ranging from 1 to 100 nM, demonstrating that CRT h 2 is the receptor responsible for regulating PGD 2 -mediated chemotaxis of BMMC.
BMMC can migrate to DK-PGD 2 in vivo and this response can be abrogated by Compound A
We subsequently wanted to test whether i.v. injected BMMC could localize to areas of high DK-PGD 2 concentration in vivo. As BMMCs migrated in response to CRT h 2 activation in vitro, we hypothesized that they should be able to so (Fig. 8A and B) . Strikingly, this in vivo migration could be blocked by orally administered Compound A.
Both the 10 and 1 mg kg À1 doses were effective at blocking BMMC migration to the exogenously administered DK-PGD 2 in each experiment. Coupled with the in vitro chemotaxis experiments, these studies show that primary BMMCs have the ability to respond functionally to CRT h 2 activation by migrating specifically to PGD 2 or DK-PGD 2 .
Discussion
This study shows that mast cells both express the CRT h 2 receptor and respond functionally to this receptor's ligands, endogenous PGD 2 and the CRT h 2-specific ligand DK-PGD 2 . CRT h 2 activation results in intracellular Ca 2+ mobilization (Fig. 4) , phosphorylation of the p42/p44 ERK kinases (Fig. 6) , shedding of L-selectin (Fig. 3A) and chemotaxis (Fig. 7) . If the responses of BMMCs are like those of mast cells in tissues in situ, then these responses may be part of a cascade necessary for in vivo migration of mast cells into tissues.
Activation of mast cells by polyvalent antigen cross-linking of cell surface-bound IgE molecules coupled with subsequent release of potent mediators make mast cells pivotal players in the initiation and maintenance of various inflammatory conditions as well as allergic responses. Furthermore, mast cell hyperplasia has been noted in various inflammatory conditions such as asthma (32), atopic dermatitis (33), allergic rhinitis (34), psoriasis (35) and rheumatoid arthritis (36) . Whether this is due to mast cell proliferation or recruitment is not well understood. Neither is the process of mast cell recruitment to inflamed tissues nor the chemotactic factors regulating this process for specific inflammatory conditions have not been defined. Some chemoattractants that have the ability to induce in vitro chemotaxis of murine BMMC include stem cell factor, IL-3, MCP-1 (CCL2), MIP-1a (CCL3), RANTES (CCL5) and LTB 4 (23, 37, 38, 39) . We demonstrate here that murine BMMCs were able to localize in the skin from the circulation in response to i.d. injected DK-PGD 2 (Fig. 8) . Furthermore, the response could be inhibited by the oral administration of potent and selective CRT h 2 antagonist. Although the experiment carried out here represents an artificial experimental system as mature BMMCs are not ordinarily found in the circulation, these results can be taken to suggest that PGD 2 may be another chemoattractant utilized to recruit mast cells to the sites of inflammation where PGD 2 is released. This attribute may play a role in exacerbating diseases such as asthma, atopic dermatitis and allergic rhinitis.
Mast cells release the arachidonic acid metabolite PGD 2 following activation and are the greatest producers of PGD 2 in the body. This raises the notion that activation-induced release of PGD 2 may result in the recruitment of mast cells to the inflammatory sites. The ability of chemoattractants to attract cells expressing counter receptors into inflamed tissues has well been established. PGD 2 has been shown to be a chemotactic for eosinophils, basophils and T h 2 helper T cells, and this could inhibited by the antagonism of CRT h 2 (13, 20) . Collectively, it is plausible that the PGD 2 -CRT h 2 system acts as an autocrine feedback loop that can attract mast cells to the sites of inflammation and PGD 2 release, resulting in amplification of the inflammatory response. CD30 is a cell surface receptor that belongs to the tumor necrosis receptor superfamily, and is up-regulated on BMMC treated with DK-PGD 2 (Fig. 3C) . Ligation of CD30 by CD30 ligand has been shown to result in the release of IL-8, MIP-1a and MIP-1b, and this process was found to be independent of IgE (40) . Hence, CRT h 2-mediated recruitment of mast cells may also prime BMMC for CD30-induced cytokine and chemokine production.
During the course of this study, we also examined whether PGD 2 or DK-PGD 2 could modulate the release of granule components, specifically histamine, or cytokine secretion, such as IL-6, TNF-a and IL-2, upon antigen-induced crosslinking of IgE-loaded BMMC. It has previously been shown that PGE 2 could potentiate IgE-mediated cytokine release and in some reports been shown to induce IL-6 and GM-CSF production by PGE 2 Tx alone (25) (26) (27) . These effects were thought to be mediated by the G ai -linked EP3 receptor. We found no effect of PGD 2 or DK-PGD 2 stimulation on either of these processes in contrast to PGE 2 , used a side-byside control (Fig. 5A-C) . Further, BMMC lost the ability to flux Ca ++ in response to PGD 2 when the cells were loaded with IgE overnight (Fig. 5D-G) . Thus, the occupancy of the high affinity IgE receptor with IgE drastically decreased BMMC responsiveness to PGD 2 in vitro. Our preliminary data indicate that this may reflect a down-regulation of CRT h 2 in such cells after exposure to IgE, at least at the mRNA level (Fig. 5H) . Down-regulation of CRT h 2 mRNA upon IgE binding in BMMC is similar to T h 2 T lymphocytes transiently down-regulating CRT h 2 mRNA and cell surface levels immediately following TCR ligation (30) . Additionally, CRT h 2 may act similarly to other G ai -linked chemoattractant GPCRs in which activation elicits a chemotactic response with no apparent effect on FceRI-mediated degranulation (41) (42) (43) . In either case, if the observed decreased BMMC responsiveness to PGD 2 in response to occupancy of the high affinity IgE receptor with IgE seen in vitro were to occur in human mast cells in vivo, then such mast cells may give little or no response to stimulation with PGD 2 . Taken together, our results suggest that CRT h 2 activation may prime mast cells with no, or perhaps minimal, FceRI occupancy with IgE for the release of inflammatory mediators, but PGD 2 does not appear to control their release directly. In summary, these results show that primary BMMCs express CRT h 2 and that the endogenous ligand, PGD 2 , is a chemotactic factor both in vitro and in vivo via activation of the CRT h 2 receptor. Mast cells are potent pro-inflammatory cells that play a key role in allergic diseases, such as atopic dermatitis and asthma, and their numbers are increased at the sites of inflammation. As mast cells also synthesize and release PGD 2 in response to activation, the CRT h 2-PGD 2 system may result in an autocrine feedback loop recruiting greater numbers of mast cells to the sites of inflammation. These observations together suggest that antagonism of CRT h 2 may be a rational therapeutic course for the Tx of allergic diseases.
